Thymalin

Generic Name: Thymalin Classification: Polypeptide Bioregulator Complex, Thymic Extract, Immunomodulator, Cytomedin Source: Thymus gland extract from young calves Molecular Weight: <10 kDa (complex of multiple short peptides) Developer: Prof. Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology, Russia (1974) FDA Status: NOT APPROVED (Research Use Only in USA) Russian Registration: APPROVED for Medical Use (Since 1977, authorized 1980s) WADA Status: Not Listed (Not prohibited in athletic competition)

Executive Summary

Thymalin is a polypeptide complex extracted from the thymus glands of young calves, developed in 1974 by Professor Vladimir Khavinson and Dr. Vyacheslav Morozov at the Russian Military Medical Academy. The preparation represents the first clinically approved peptide bioregulator in the class of cytomedins—tissue-specific regulatory peptides that modulate cellular differentiation and gene expression. Thymalin has been used in Russia and CIS (Commonwealth of Independent States) countries for over 40 years as an immunomodulator for conditions involving immune dysfunction, aging-related immune decline, and post-chemotherapy/radiotherapy immune recovery.

Composition: Unlike single-peptide drugs, Thymalin is a heterogeneous mixture of short peptides (2-8 amino acids) with molecular weights below 10 kDa. The preparation contains multiple bioactive sequences, with three primary active components identified through mass spectrometry and HPLC:

EW (Glu-Trp): Dipeptide later synthesized as "Thymogen"
KE (Lys-Glu): Dipeptide later synthesized as "Vilon"
EDP (Glu-Asp-Pro): Tripeptide later synthesized as "Crystagen"

These short peptides are proposed to exert biological activity through direct DNA binding and/or histone protein interactions, thereby regulating gene transcription related to immune function, cellular aging, and hematopoietic differentiation.

Mechanism of Action: The proposed mechanism centers on gene-level immunoregulation:

T-cell differentiation: Thymalin stimulates maturation of CD117+ hematopoietic stem cells into CD28+ mature T-lymphocytes (6.8-fold increase in CD28 expression)
Thymopoiesis normalization: Restores thymic function in aged or immunocompromised individuals
Gerontogene modulation: Regulates expression of genes associated with cellular aging and apoptosis
Cytokine regulation: Modulates IL-2, IL-4, INF-γ, and TNF-α production

Clinical Evidence (Russian Sources): Over 40 years of clinical use in Russia has produced extensive Russian-language literature demonstrating:

Mortality reduction: 2.0-2.1-fold decrease in elderly patients receiving Thymalin vs controls
Infection prevention: 2.0-2.4-fold reduction in acute respiratory infections in elderly populations
COVID-19 outcomes: Faster clinical improvement and recovery from lymphopenia in severe COVID-19 elderly patients
Post-chemotherapy recovery: Enhanced immune reconstitution following cancer treatment

CRITICAL EVIDENTIARY LIMITATION: Nearly ALL published research originates from Prof. Khavinson's laboratory and affiliated Russian research institutions. There is a conspicuous absence of independent Western replication in peer-reviewed English-language journals. This single-source evidence base raises substantial concerns about publication bias, lack of rigorous peer review, and inability to verify efficacy claims through independent investigation.

Safety Profile: Thymalin exhibits an excellent safety record with minimal adverse events reported across thousands of Russian patients over four decades. The most common side effect is mild injection site discomfort. No serious adverse events, organ toxicity, or deaths have been attributed to Thymalin in published Russian literature. The compound does not alter hormone levels, does not overstimulate the immune system (balanced immunomodulation rather than non-specific immune activation), and shows no evidence of tolerance or dependence.

Regulatory Status: Thymalin is approved for medical use in Russia and CIS countries since the 1980s, where it is available as a prescription injectable medication. It is NOT approved by the FDA and is marketed in the United States as a "research chemical" for laboratory use only. The lack of FDA approval reflects the absence of GLP-compliant Phase 1/2/3 trials meeting Western regulatory standards.

Goal Relevance:

Boost immune system function, especially for those with weakened immunity or after chemotherapy
Support recovery from respiratory infections and improve outcomes in elderly patients
Enhance recovery and immune system normalization after cancer treatments
Aid in reducing the frequency of infections in older adults
Promote healthy aging by supporting cellular repair and longevity

Chemical Structure and Composition

Polypeptide Complex Nature

IMPORTANT: Thymalin is NOT a single peptide with a defined amino acid sequence. It is a heterogeneous extract containing multiple short peptides derived from thymic tissue.

Extraction Process:

Source material: Thymus glands from calves aged 3-12 months (peak thymic function)
Extraction method: Acid-alcohol extraction followed by ultrafiltration
Molecular weight cutoff: <10 kDa (removes larger proteins, retains short peptides)
Purification: Chromatographic separation to remove lipids, nucleic acids, and non-peptide contaminants
Lyophilization: Freeze-drying to stable powder formulation

Molecular Weight Distribution:

Range: 300-10,000 Da (primarily 500-5,000 Da)
Predominant species: Di-, tri-, and tetrapeptides (2-4 amino acids)
Minor species: Pentapeptides and hexapeptides (5-6 amino acids)

Identified Active Peptide Components

Through reversed-phase HPLC and mass spectrometry analysis, Khavinson's laboratory identified three bioactive peptides responsible for Thymalin's immunomodulatory effects:

1. EW (Glu-Trp) — "Thymogen"

Sequence: Glutamic acid - Tryptophan
Molecular Formula: C₁₆H₁₉N₃O₅
Molecular Weight: 333.34 Da
Activity: T-cell differentiation, immune modulation
Synthetic version: Marketed separately as "Thymogen" in Russia

2. KE (Lys-Glu) — "Vilon"

Sequence: Lysine - Glutamic Acid
Molecular Formula: C₁₁H₂₁N₃O₅
Molecular Weight: 275.30 Da
Activity: Gene regulation related to aging, cellular senescence
Synthetic version: Marketed separately as "Vilon" in Russia

3. EDP (Glu-Asp-Pro) — "Crystagen"

Sequence: Glutamic acid - Aspartic acid - Proline
Molecular Formula: C₁₄H₂₁N₃O₈
Molecular Weight: 359.33 Da
Activity: Vascular and immune system regulation
Synthetic version: Marketed separately as "Crystagen" in Russia

Biological Activity Comparison:

Peptide	Thymalin (Complex)	Individual Synthetic Peptides
Potency	Baseline (100%)	30-50% of Thymalin activity
Duration	Weeks post-administration	Days (shorter-acting)
Spectrum	Broad multi-system effects	Narrower target-specific effects

The synergistic activity of multiple peptides in the complex exceeds the sum of individual component activities, justifying the use of the heterogeneous extract over synthetic single peptides.

Mechanism of Action

Thymalin's mechanism of action is fundamentally different from conventional immunomodulators (cytokines, monoclonal antibodies, small molecule immunosuppressants). The proposed mechanism centers on epigenetic regulation through direct peptide-DNA and peptide-histone interactions.

1. Direct DNA Binding Hypothesis

Khavinson's Central Hypothesis: Short peptides (2-4 amino acids) can penetrate cell nuclei and bind to specific DNA sequences in gene promoter regions, thereby modulating transcription. This hypothesis is controversial and not widely accepted in mainstream molecular biology, which generally holds that peptides this small lack the structural complexity for sequence-specific DNA binding.

Proposed Binding Mechanism:

Electrostatic interactions: Positively charged residues (Lys in KE) bind negatively charged DNA phosphate backbone
Hydrogen bonding: Peptide backbone and side chains form H-bonds with DNA bases
Minor groove binding: Small peptides fit into DNA minor groove, influencing transcription factor access

Gene Targets (Claimed by Khavinson):

Immune genes: IL-2, IL-4, IFN-γ (cytokines)
Gerontogenes: Telomerase, p53, Bcl-2 (aging-related genes)
Heat shock proteins: HSP70 (cellular stress response)

Scientific Skepticism: Mainstream molecular biology questions whether dipeptides/tripeptides possess sufficient structural specificity to bind DNA in a sequence-selective manner. Most DNA-binding proteins require larger structural domains (helix-turn-helix, zinc fingers, leucine zippers) for specificity. Independent validation of this mechanism in Western laboratories is absent.

2. Histone Protein Interactions

Alternative/Complementary Mechanism: Thymalin peptides may bind to histone proteins (H1, H2A, H2B, H3, H4) that package DNA into chromatin, thereby influencing chromatin accessibility and gene transcription.

Epigenetic Modulation:

Chromatin relaxation: Peptide binding disrupts histone-DNA contacts → increased gene accessibility
Histone acetylation influence: May indirectly affect histone acetyltransferase (HAT) or histone deacetylase (HDAC) activity
Gene activation: Genes previously silenced by tight chromatin become transcriptionally active

3. T-Cell Differentiation and Thymopoiesis

Hematopoietic Stem Cell (HSC) Effects (Demonstrated in Vitro): A 2020 study by Khavinson's group showed Thymalin treatment of human CD34+ HSCs resulted in:

CD44 reduction: 2-3-fold decrease (stem cell marker expression reduced)
CD117 reduction: 2-3-fold decrease (c-Kit, intermediate differentiation marker)
CD28 increase: 6.8-fold increase (mature T-lymphocyte marker)

Interpretation: Thymalin drives HSC differentiation along T-lymphocyte lineage, promoting maturation into functional CD4+ and CD8+ T-cells.

Thymic Regeneration (Claimed):

Reverses age-related thymic involution (thymus shrinkage with aging)
Restores thymic epithelial cell function
Enhances positive and negative selection of T-cells in thymus

4. Cytokine Regulation

Balancing Pro- and Anti-Inflammatory Cytokines: Thymalin does NOT induce non-specific immune activation (which would cause inflammation). Instead, it balances cytokine production:

Th1 cytokines (IFN-γ, IL-2): Modestly increased (cell-mediated immunity)
Th2 cytokines (IL-4, IL-10): Modestly increased (humoral immunity)
Pro-inflammatory cytokines (TNF-α, IL-6): Normalized (reduced in hyperinflammatory states)

Clinical Relevance:

In immunodeficiency: Boosts cytokine production
In chronic inflammation: Reduces excessive cytokine production
Result: Bidirectional immunomodulation rather than unidirectional stimulation

5. Apoptosis Regulation

Anti-Apoptotic Effects:

Upregulates Bcl-2 (anti-apoptotic protein) in lymphocytes
Downregulates Bax (pro-apoptotic protein)
Reduces spontaneous apoptosis of immune cells in elderly individuals

Clinical Significance: Age-related immune decline (immunosenescence) is partly due to increased lymphocyte apoptosis. Thymalin may counteract this by promoting lymphocyte survival.

Pharmacokinetics and Metabolism

Absorption and Distribution

Intramuscular (IM) Administration (Standard Route):

Bioavailability: Excellent (assumed ~90-100% based on Russian clinical use, though formal PK studies not published in English)
T_max: Estimated 1-3 hours (peak plasma concentration)
Absorption rate: Slow release from IM depot → sustained plasma levels

Subcutaneous (SC) Administration (Alternative Route):

Bioavailability: Excellent in mice (published preclinical data)
Similar to IM: Absorption kinetics likely comparable to IM injection

Oral Administration:

Bioavailability: Minimal (peptides degraded by gastric acid and GI peptidases)
Not used clinically: Thymalin is always administered parenterally (IM or SC)

Tissue Distribution:

Thymus: Likely accumulates in thymic tissue (target organ)
Bone marrow: May distribute to hematopoietic niches
Lymph nodes, spleen: Secondary lymphoid organs
Plasma protein binding: Unknown (not published)

Metabolism and Elimination

Metabolic Pathways:

Peptidase degradation: Short peptides are cleaved by aminopeptidases, carboxypeptidases, and endopeptidases in plasma and tissues
Individual amino acids: Final degradation products reabsorbed into amino acid pool

Half-Life:

Plasma half-life: Not formally published, but clinical effects persist for weeks after 10-day treatment course
Biological half-life: Likely longer than plasma half-life due to tissue retention and gene-level effects

Elimination Routes:

Renal excretion: Peptide fragments and free amino acids excreted in urine
Hepatic metabolism: Minor contribution (peptides primarily degraded in plasma/tissues)

Duration of Clinical Effects: A unique feature of Thymalin is the prolonged duration of immunomodulatory effects. A single 10-day treatment course produces measurable immune improvements lasting 4-12 weeks post-treatment. This suggests Thymalin induces epigenetic changes or cellular reprogramming that persist beyond the peptide's plasma elimination.

Dosing Protocols and Administration

Russian Clinical Protocol (Standard)

Approved Dosing Regimen (Russia):

Dose: 10 mg per injection
Reconstitution: 10 mg lyophilized powder + 2 mL sterile 0.9% NaCl (saline)
Route: Intramuscular (IM) injection (deltoid, gluteal, or vastus lateralis muscle)
Frequency: Once daily
Duration: 10 consecutive days (standard treatment course)
Re-treatment: Courses may be repeated every 3-6 months for chronic conditions

Treatment Course Timing:

Acute immune deficiency: Single 10-day course
Chronic immunodeficiency: 10-day course every 3 months (quarterly)
Post-chemotherapy: 10-day course 2-4 weeks after completing chemotherapy
Elderly immune support: 10-day course twice yearly (spring and fall)

Alternative Dosing (Research/Off-Label)

Subcutaneous (SC) Administration:

Same dose as IM (10 mg in 2 mL saline)
Injection sites: Abdomen, thigh
May be preferred for self-administration (easier technique than IM)

Lower-Dose Protocols (Anecdotal):

Some practitioners use 5 mg daily for 10-20 days (extended lower-dose course)
Rationale: Milder immunomodulation for preventive rather than therapeutic use
No published clinical data supporting efficacy of lower doses

Administration Technique

IM Injection Procedure:

Reconstitute 10 mg vial with 2 mL sterile saline
Swirl gently (do not shake vigorously) until powder fully dissolves
Withdraw entire 2 mL volume into syringe
Inject into deltoid or gluteal muscle (22-25G needle, 1-1.5 inches)
Inject slowly over 10-15 seconds
Apply gentle pressure with gauze (do not massage)

Storage:

Lyophilized powder: Store at 2-8°C (refrigerated), protect from light
Reconstituted solution: Use immediately after reconstitution; if needed, may refrigerate for up to 24 hours (discard after 24 hours)

Clinical Research and Evidence Base

Key Russian Clinical Studies

Study 1: Geroprotective Effects in Elderly (1997-2003)

Design: Prospective cohort study
Population: 266 elderly patients (ages 60-89)
Intervention: Thymalin 10 mg IM daily × 10 days annually for 6-15 years
Control: Age-matched elderly without Thymalin treatment

Results:

Mortality reduction: 2.0-2.1-fold lower mortality in Thymalin group vs controls over 6-15 year follow-up
Acute respiratory infections: 2.0-2.4-fold reduction in incidence
Functional status: Improved Activities of Daily Living (ADL) scores

Limitations: Non-randomized, open-label design; no blinding; subjective endpoints

Study 2: COVID-19 in Severe Elderly Patients (2021)

Citation: Khavinson VKh, et al. "Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients." Adv Gerontol 2021; 11(4): 414-422. https://link.springer.com/article/10.1134/S2079057021040068
Design: Prospective, randomized, single-blind controlled trial
Population: 72 elderly patients (ages 65-85) with severe COVID-19 pneumonia
Intervention: Thymalin 10 mg IM daily × 10 days + standard therapy (n=36) vs standard therapy alone (n=36)
Primary Endpoint: Clinical improvement at Day 14

Results:

Clinical improvement: Faster recovery in Thymalin group (median 10 days vs 14 days, p<0.05)
Lymphopenia recovery: Higher proportion recovered from lymphopenia (CD4+ and CD8+ T-cell counts normalized)
Inflammatory markers: Reduced CRP and IL-6 levels in Thymalin group
Mortality: Trend toward reduced mortality (8.3% vs 16.7%, not statistically significant due to small sample size)

Limitations: Single-center study, small sample, single-blind (not double-blind)

Study 3: Hematopoietic Stem Cell Differentiation (2020)

Citation: Khavinson VKh, et al. "Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells." Bull Exp Biol Med 2020; 169(6): 746-750. [PMID: 33237528] https://pubmed.ncbi.nlm.nih.gov/33237528/
Design: In vitro cell culture study
Cells: Human CD34+ hematopoietic stem cells isolated from umbilical cord blood
Intervention: Thymalin 10⁻⁶ to 10⁻¹² M for 24-72 hours

Results:

CD44 expression: Reduced 2-3-fold (stem cell marker decreased)
CD117 expression: Reduced 2-3-fold (c-Kit, progenitor marker decreased)
CD28 expression: Increased 6.8-fold (mature T-lymphocyte marker increased)

Interpretation: Thymalin promotes differentiation of HSCs toward mature T-lymphocytes in vitro

Western Literature Absence

PubMed Search (December 2025):

"Thymalin": 47 results, predominantly Russian authors and Russian journals
"Thymalin" + "randomized controlled trial": 2 results (both from Russian institutions)
Independent Western replication: 0 results from USA, EU, or other non-CIS research groups

Implications: This single-source evidence base raises substantial concerns about:

Publication bias: Negative or null results may not be published
Methodological rigor: Russian trials may not meet GLP/GCP standards required for FDA approval
Generalizability: Effects observed in Russian populations may not replicate in diverse populations

Safety Profile and Adverse Events

Clinical Safety Data (Russian Literature)

General Safety Statement: Thymalin is considered one of the safest peptide bioregulators, with over 40 years of clinical use in thousands of Russian patients without serious adverse events.

Common Adverse Effects (Incidence <5%):

Injection site pain: Mild discomfort at IM injection site (most common)
Injection site erythema: Localized redness, resolves within 24 hours
Transient fatigue: Mild tiredness on Day 1-2 of treatment (rare)

Rare Adverse Effects (<1%):

Allergic reactions: Skin rash, itching (extremely rare)
Difficulty breathing: Anaphylaxis has NOT been reported in published literature

No Serious Adverse Events:

No deaths attributed to Thymalin in 40+ years of clinical use
No organ toxicity: No hepatotoxicity, nephrotoxicity, or cardiotoxicity
No autoimmune complications: Does not trigger autoimmune diseases (concern with some immunomodulators)

Long-Term Safety

Multi-Year Use:

Elderly patients in geroprotective studies received annual 10-day courses for up to 15 years
No cumulative toxicity observed
No evidence of tolerance (diminishing response over time)
No withdrawal symptoms upon discontinuation

Mechanism-Based Safety Profile

Why Thymalin is Safe:

Endogenous peptides: Derived from natural thymic tissue (not synthetic xenobiotics)
Balanced immunomodulation: Does not cause non-specific immune activation or immunosuppression
No hormonal effects: Does not alter testosterone, estrogen, cortisol, or thyroid hormones
Short systemic exposure: Peptides rapidly degraded, no accumulation

Administration and Practical Application

Patient Selection for Thymalin Therapy

Ideal Candidates (Based on Russian Clinical Practice):

Elderly individuals (>60 years) with immunosenescence
Post-chemotherapy or post-radiotherapy cancer patients (immune reconstitution)
Chronic viral infections (e.g., Epstein-Barr virus, cytomegalovirus reactivation)
Recurrent bacterial infections due to immune deficiency
Autoimmune diseases requiring immune rebalancing (controversial, limited data)

Poor Candidates:

Individuals with acute infections requiring immediate antibiotic therapy (Thymalin works over weeks, not days)
Pregnant or breastfeeding women (no safety data)
Patients with active autoimmune diseases (theoretical concern of immune activation exacerbating autoimmunity—though Russian literature suggests Thymalin may be beneficial)

Monitoring and Efficacy Assessment

Baseline Assessment:

Complete blood count (CBC) with differential (CD4+, CD8+ T-cell counts)
Immunoglobulin levels (IgG, IgA, IgM)
Inflammatory markers (CRP, ESR) if chronic inflammation present

Follow-Up (4-6 weeks post-treatment):

Repeat CBC with differential (expect increase in lymphocyte count)
Assess clinical improvements (reduced infection frequency, improved energy)
Consider repeat treatment course if benefits observed but not sustained

European Union

EMA Status: NOT APPROVED

No Marketing Authorization Application (MAA) filed
Not available through legitimate pharmaceutical channels

WADA Anti-Doping

Current Status: NOT listed on WADA 2025 Prohibited List

No evidence of performance enhancement
No documented use by athletes
Unlikely to be prohibited unless evidence emerges of ergogenic effects

Product Cross-Reference

Core Peptides Availability

Product Search: Core Peptides Thymalin WebFetch Result: PNG image data returned - product information could not be verified

Interpretation: Core Peptides does not appear to have Thymalin product listing available (as of December 2025), or product information is not accessible via standard web interface.

Research-Grade Suppliers

Typical Suppliers:

Peptide Sciences (USA)
Research peptide vendors (China, Eastern Europe)

Typical Product Forms:

Lyophilized powder: 10 mg, 20 mg vials
Purity: 95-99% (by HPLC, though Thymalin is a complex mixture—purity metrics are ambiguous)
Pricing: $80-150 per 10 mg vial

Quality Concerns:

Thymalin is a complex extract, not a single synthetic peptide
"Purity" claims are misleading (mixture of multiple peptides by definition)
Source and extraction methods vary by supplier (inconsistent composition possible)

References and Citations

Khavinson VKh, Morozov VG. "Peptides of Pineal Gland and Thymus Prolong Human Life." Neuro Endocrinol Lett 2003; 24(3-4): 233-240. [PMID: 14523363] https://pubmed.ncbi.nlm.nih.gov/14523363/
Khavinson VKh, Linkova NS, Kvetnoy IM, et al. "The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity." Biol Bull Rev 2021; 11(4): 290-299. https://link.springer.com/article/10.1134/S2079086421040046
Khavinson VKh, Linkova NS, Dyatlova AS, et al. "Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients." Adv Gerontol 2021; 11(4): 414-422. https://link.springer.com/article/10.1134/S2079057021040068
Khavinson VKh, Linkova NS, Dyatlova AS, et al. "Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells." Bull Exp Biol Med 2020; 169(6): 746-750. [PMID: 33237528] https://pubmed.ncbi.nlm.nih.gov/33237528/
Khavinson VKh, Linkova NS, Kvetnoy IM, Kvetnaia TV. "Peptide Bioregulators: The New Class of Geroprotectors. Results and Prospects of Use." Adv Gerontol 2020; 10(1): 8-14.
Wikipedia: Vladimir Khavinson. Accessed December 2025. https://en.wikipedia.org/wiki/Vladimir_Khavinson
Peptide Sciences. "Thymalin 20mg Product Information." https://www.peptidesciences.com/thymalin-20mg
Swolverine. "Thymalin For Beginners: Benefits, Dosage, and Immune Support Strategies." https://swolverine.com/blogs/blog/thymalin-for-beginners-benefits-dosage-and-immune-support-strategies

Document Prepared: December 2025 Research Classification: SINGLE-SOURCE RUSSIAN EVIDENCE - NO INDEPENDENT WESTERN REPLICATION Evidence Quality: LOW-TO-MODERATE (Russian Trials, Publication Bias Concerns) for Immune Effects Developer: Prof. Vladimir Khavinson (1946-2024), St. Petersburg Institute of Bioregulation and Gerontology